Health Canada approves Kynmobi for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease .- Sunovion

Sunovion Pharmaceuticals Inc. announced on 15 June 2020 hat Health Canada has approved Kynmobi (apomorphine HCI) soluble film for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re-emergence or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa.

They may be characterized, in part, by tremor, stiffness, slowed movement or other symptoms. These disruptive episodes can occur any time throughout the day and get worse as the disease progresses. Kynmobi was previously approved by the FDA on May 21, 2020.

“The unpredictable and frequent nature of OFF episodes, which can occur despite people taking their oral maintenance medications as prescribed, makes this a particularly challenging and burdensome facet of Parkinson’s disease,” said Anthony E. Lang, M.D., Professor at University of Toronto and Jack Clark Chair for Parkinson’s Disease Research, and Director of the Edmond J Safra Program in Parkinson’s disease at Toronto Western Hospital. “Kynmobi is a welcome on-demand treatment that physicians can offer patients to help rapidly improve their PD OFF episodes.”